Development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics

被引:1
作者
Fu, Chenchun [1 ]
Feng, Shicheng [1 ]
Wang, Sheng [1 ]
Su, Xiangyu [1 ]
机构
[1] Southeast Univ, Zhongda Hosp, Dept Oncol, Nanjing 210009, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 02期
关键词
esophageal cancer; immunotherapy; prognosis; tumor microenvironment; tumor mutation burden; SQUAMOUS-CELL CARCINOMA; ANALYSIS REVEALS; CANCER-TREATMENT; CTLA-4; BLOCKADE; OPEN-LABEL; IMMUNOTHERAPY; RADIOTHERAPY; LANDSCAPE; RADIATION; CHEMOTHERAPY;
D O I
10.1002/cam4.4985
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Esophageal cancer (EC) is an aggressive malignancy that accounts for numerous cancer-related deaths worldwide. The multimodal combination therapy approach can be potentially used to treat EC effectively. However, distinct biomarker of significant specificity are still needed to develop individualized treatment strategies and provide accurate prognostic predictions. Therefore, we aimed to investigate the associated genes subtypes identified were, IFN-gamma Dominant, Inflammatory, Lymphocyte Depleted, etc. and construct a risk model based on these genes to predict the overall survival (OS) of patients suffering from EC. Three immune subtypes were defined in the Cancer Genome Atlas (TCGA) cohort with different tumor microenvironment (TME) and clinical outcomes based on radio-differentiated immune genes. Subsequently, a risk model of immune characteristics included the immune cell infiltration levels and pathway activity was developed based on the genomic changes between the subtypes. In the TCGA dataset, as well as in subgroup analysis with different stages, gender, age, and pathological type, a high-risk score was identified as an adverse factor for OS using the method of the univariate Cox regression analysis and tROC analysis. Furthermore, it was observed that the high-risk group was characterized by depleted immunophenotype, active cell metabolism, and a high tumor mutation burden (TMB). The low-risk group was characterized by high TME abundance and active immune function. Differences in the biological genotypes may account for the differences in the prognosis and treatment response. Extensive research was carried out, and the results revealed that the low-risk group exhibited a significant level of therapeutic advantage in the field of immunotherapy. A risk model was developed based on the immune characteristics. It can be used to optimize risk stratification for patients suffering from EC. The results can potentially help provide new perspectives on treatment methods.
引用
收藏
页码:2089 / 2103
页数:15
相关论文
共 63 条
  • [1] Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer
    Allum, William H.
    Stenning, Sally P.
    Bancewicz, John
    Clark, Peter I.
    Langley, Ruth E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) : 5062 - 5067
  • [2] Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
    Bernstein, Michael B.
    Krishnan, Sunil
    Hodge, James W.
    Chang, Joe Y.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) : 516 - 524
  • [3] ImmPort, toward repurposing of open access immunological assay data for translational and clinical research
    Bhattacharya, Sanchita
    Dunn, Patrick
    Thomas, Cristel G.
    Smith, Barry
    Schaefer, Henry
    Chen, Jieming
    Hu, Zicheng
    Zalocusky, Kelly A.
    Shankar, Ravi D.
    Shen-Orr, Shai S.
    Thomson, Elizabeth
    Wiser, Jeffrey
    Butte, Atul J.
    [J]. SCIENTIFIC DATA, 2018, 5
  • [4] Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
    Bindea, Gabriela
    Mlecnik, Bernhard
    Tosolini, Marie
    Kirilovsky, Amos
    Waldner, Maximilian
    Obenauf, Anna C.
    Angell, Helen
    Fredriksen, Tessa
    Lafontaine, Lucie
    Berger, Anne
    Bruneval, Patrick
    Fridman, Wolf Herman
    Becker, Christoph
    Pages, Franck
    Speicher, Michael R.
    Trajanoski, Zlatko
    Galon, Jerome
    [J]. IMMUNITY, 2013, 39 (04) : 782 - 795
  • [5] BRAY F, 2018, CA-CANCER J CLIN, V68, P394, DOI [DOI 10.3322/CANJCLIN.49.1.33, DOI 10.3322/CAAC.21492]
  • [6] Development of immune gene pair-based signature predictive of prognosis and immunotherapy in esophageal cancer
    Cao, Kui
    Ma, Tianjiao
    Ling, Xiaodong
    Liu, Mingdong
    Jiang, Xiangyu
    Ma, Keru
    Zhu, Jinhong
    Ma, Jianqun
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (20)
  • [7] The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership
    Chajon, Enrique
    Castelli, Joel
    Marsiglia, Hugo
    De Crevoisier, Renaud
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 111 : 124 - 132
  • [8] Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
    Chalmers, Zachary R.
    Connelly, Caitlin F.
    Fabrizio, David
    Gay, Laurie
    Ali, Siraj M.
    Ennis, Riley
    Schrock, Alexa
    Campbell, Brittany
    Shlien, Adam
    Chmielecki, Juliann
    Huang, Franklin
    He, Yuting
    Sun, James
    Tabori, Uri
    Kennedy, Mark
    Lieber, Daniel S.
    Roels, Steven
    White, Jared
    Otto, Geoffrey A.
    Ross, Jeffrey S.
    Garraway, Levi
    Miller, Vincent A.
    Stephens, Phillip J.
    Frampton, Garrett M.
    [J]. GENOME MEDICINE, 2017, 9
  • [9] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
    Chan, T. A.
    Yarchoan, M.
    Jaffee, E.
    Swanton, C.
    Quezada, S. A.
    Stenzinger, A.
    Peters, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (01) : 44 - 56
  • [10] TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
    Colaprico, Antonio
    Silva, Tiago C.
    Olsen, Catharina
    Garofano, Luciano
    Cava, Claudia
    Garolini, Davide
    Sabedot, Thais S.
    Malta, Tathiane M.
    Pagnotta, Stefano M.
    Castiglioni, Isabella
    Ceccarelli, Michele
    Bontempi, Gianluca
    Noushmehr, Houtan
    [J]. NUCLEIC ACIDS RESEARCH, 2016, 44 (08) : e71